Nicotinamide

• Description:

  Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM) . Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity[1][2][3][4].

• Product Name Alternative:

  Niacinamide; Nicotinic acid amide

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Endogenous Metabolite; HBV; Organoid; Sirtuin

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; Stem Cell/Wnt

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Nicotinamide.html

• Purity:

  99.99

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

• Smiles:

  O=C(C1=CC=CN=C1)N

• Molecular Formula:

  C6H6N2O

• Molecular Weight:

  122.13

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Francesca Scatozza, et al. Nicotinamide inhibits melanoma in vitro and in vivo. J Exp Clin Cancer Res. 2020 Oct 7;39 (1) :211.|[2]Hwang ES, et al. Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells. Cell Mol Life Sci. 2017 Sep;74 (18) :3347-3362. |[3]Li WY, et al. The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo. Arch Virol. 2016 Mar;161 (3) :621-30. |[4]Zhang Y, et al. Nicotinamide promotes pancreatic differentiation through the dual inhibition of CK1 and ROCK kinases in human embryonic stem cells. Stem Cell Res Ther. 2021 Jun 25;12 (1) :362.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Isoform:

  Human Endogenous Metabolite; SIRT1; SIRT2

• Citation 01:

  Acta Pharm Sin B. 2025 Aug 21.|Acta Pharm Sin B. 2025 Sep 19.|Aging Cell. 2021 Oct 3; e13491.|Am J Cancer Res. 2023 Feb 15;13 (2) :464-474.|Am J Physiol Heart Circ Physiol. 2021 Aug 1;321 (2) :H353-H368.|Apoptosis. 2025 Apr;30 (3-4) :768-783.|Autophagy. 2020 Oct;16 (10) :1823-1837.|Biochim Biophys Acta Mol Basis Dis. 2025 May 13:167904.|bioRxiv. 2020 Mar.|bioRxiv. 2023 Jun 6.|bioRxiv. 2025 Apr 26:2025.04.23.650241.|bioRxiv. 2025 April 30.|bioRxiv. 2025 Aug 02.|bioRxiv. 2025 March 24.|bioRxiv. 2025 Oct 14.|Br J Haematol. 2024 Dec;205 (6) :2432-2441.|Cancer Cell. 2024 Oct 14;42 (10) :1729-1746.e8.|Cancer Lett. 2024 Jun 14:597:217005.|Cardiovasc Toxicol. 2022 Nov;22 (10-11) :898-909.|Cell Death Differ. 2023 Nov;30 (11) :2382-2392.|Cell Death Dis. 2021 Sep 23;12 (10) :865.|Cell Death Discov. 2022 May 17;8 (1) :265.|Cell Discov. 2024 Sep 17;10 (1) :96.|Cell Mol Life Sci. 2025 Apr 6;82 (1) :139.|Cell Mol Life Sci. 2025 Apr 7;82 (1) :140.|Cell Mol Life Sci. 2025 Oct 24;82 (1) :361.|Cell Prolif. 2024 Apr 16:e13646.|Cell Rep Med. 2025 Feb 18;6 (2) :101966.|Cell Signal. 2024 Sep 5:111386.|Cell Stem Cell. 2022 Sep 1;29 (9) :1366-1381.e9.|Chin J Integr Med. 2025 Feb;31 (2) :118-130.|Circ Res. 2022 Aug 19;131 (5) :456-472.|Commun Biol. 2023 Mar 2;6 (1) :235.|Commun Biol. 2025 Jul 4;8 (1) :995.|Ecotoxicol Environ Saf. 2024 Jul 18:282:116733.|EMBO J. 2020 Sep 15;39 (18) :e104365.|EMBO Rep. 2025 Aug;26 (16) :4100-4123.|Exp Cell Res. 2022 Dec 15;421 (2) :113404.|Hum Cell. 2024 Nov 4;38 (1) :13.|Hum Reprod. 2019 Jul 8;34 (7) :1186-1194.|Hum Reprod. 2020 Mar 27;35 (3) :494-503. |Int Immunopharmacol. 2023 Jul:120:110279.|Int J Biol Macromol. 2024 Jul 27:134120.|Int J Biol Macromol. 2025 Jan 7:139619.|Int J Mol Sci. 2022 Aug 12;23 (16) :9049.|iScience. 2024 Aug 21;27 (9) :110775.|iScience. 2025 Apr 3;28 (5) :112344.|iScience. 2025 Sep 9;28 (10) :113520.|J Adv Res. 2025 Jul 12:S2090-1232 (25) 00545-4.|J Exp Clin Cancer Res. 2023 Jan 5;42 (1) :5.|J Exp Clin Cancer Res. 2025 Feb 24;44 (1) :67.|J Ginseng Res. 2022 Nov;46 (6) :759-770.|J Immunol. 2022 Aug 1;209 (3) :476-487.|J Mol Cell Cardiol. 2022 Dec:173:154-168.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Proteomics. 2023 May 30:280:104889.|J Proteomics. 2024 May 24:105213.|Mol Cell. 2025 Apr 3;85 (7) :1349-1365.e10.|Molecules. 2025 Oct 14;30 (20) :4082.|Nat Commun. 2021 Jul 9;12 (1) :4227.|Nat Commun. 2021 Sep 20;12 (1) :5548.|Nat Commun. 2023 Sep 22;14 (1) :5917.|Nat Commun. 2025 Mar 5;16 (1) :2200.|Nat Genet. 2023 Dec;55 (12) :2175-2188.|Nat Photonics. 2025 Jul 10.|NPJ Precis Oncol. 2025 May 16;9 (1) :143.|Oncogene. 2020 Mar;39 (11) :2437-2449. |Oncogene. 2024 Oct;43 (43) :3170-3183.|Oncoimmunology. 2025 Dec;14 (1) :2460281.|Oxid Med Cell Longev. 2021 Jan 19;2021:6610543.|Patent. US20180263995A1.|Patent. US20250129329A1.|PeerJ. 2023 May 11:11:e15258.|Pharmacol Res. 2024 Dec 31:107573.|Phytomedicine. 2025 Oct 15:148:157384.|PLoS Pathog. 2024 Mar 12;20 (3) :e1012082.|Redox Biol. 2025 Aug 19:86:103834.|Res Sq. 2025 Jul 14.|Research Square Preprint. 2022 Feb.|SSRN. 2024 May 30.|Theranostics. 2019 Apr 13;9 (9) :2424-2438.|Theriogenology. 2020 Dec;158:233-238.|Tissue Cell. 2025 Aug:95:102884.|Sci Adv. 2024 Jun 21;10 (25) :eadj8650.

• CAS Number:

  [98-92-0]